Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
13 mai 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
13 mai 2024 07h30 HE
|
BridgeBio Pharma, Inc.
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality...
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
13 mai 2024 01h00 HE
|
VALNEVA
Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty...
HEALWELL AI to Announce Fiscal First Quarter 2024 Financial Results on May 14, 2024
10 mai 2024 07h00 HE
|
HEALWELL AI Inc.
HEALWELL AI to Announce Fiscal First Quarter 2024 Financial Results on May 14, 2024
ORYZON to Provide Corporate Progress Updates at Several Events in May
09 mai 2024 08h00 HE
|
Oryzon Genomics, S.A.
Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
Spectral AI Announces 2024 First Quarter Financial Results
07 mai 2024 16h15 HE
|
Spectral AI, Inc.
Q1 Overview Research & Development Revenue of $6.3 MillionImproved Capital Structure Reflected in Cash of $10.2 MillionDeepView AI®-Burn Devices Deployed in UK; Expect Commercial Revenue in 2H...
Cogent Biosciences Reports First Quarter 2024 Financial Results
07 mai 2024 08h00 HE
|
Cogent Biosciences, Inc.
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient...
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer
07 mai 2024 07h00 HE
|
CMR Surgical
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer Shlomi Cohen is a medical devices expert with significant financial and operational experience. CAMBRIDGE, UK – 7 May 2024, 07:00...
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer
07 mai 2024 02h00 HE
|
CMR Surgical
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer Shlomi Cohen is a medical devices expert with significant financial and operational experience. CAMBRIDGE, UK – 7 May 2024, 07:00...
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
07 mai 2024 01h00 HE
|
VALNEVA
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on...